Preparation of factor Xa derivatives
The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a plurality of two-chain polypeptides each comprising a light chain and a heavy chain, wherein the two-chain polypeptides are obtainable by processing a single-chain precursor polypeptide, and wherein:
about 35%-60% of the light chains consist of the amino acid sequence of SEQ ID NO: 4;
about 20%-60% of the heavy chains consist of the amino acid sequence of SEQ ID NO: 5;
about 40%-60% of the heavy chains consist of the amino acid sequence of SEQ ID NO: 8; and
less than 10% of heavy chains consist of the amino acid sequence of SEQ ID NO: 9.
2. The pharmaceutical composition of claim 1 , wherein less than 5% of the heavy chain consist of the amino acid sequence of SEQ ID NO: 9.
3. The pharmaceutical composition of claim 1 , wherein less than 3% of the heavy chain consist of the amino acid sequence of SEQ ID NO: 9.
4. The pharmaceutical composition of claim 1 , wherein about 0.1%-1.5% of the heavy chains consist of the amino acid sequence of SEQ ID NO: 10.
5. The pharmaceutical composition of claim 1 , wherein about 2%-8% of the heavy chains consist of the amino acid sequence of SEQ ID NO: 11.
6. The pharmaceutical composition of claim 1 , wherein about 30%-70% of the heavy chains consisting of the amino acid sequence of SEQ ID NO: 5 have two O-linked glycosylations.
7. The pharmaceutical composition of claim 1 , wherein about 30%-70% of the heavy chains consisting of the amino acid sequence of SEQ ID NO: 5 have one O-linked glycosylation.
8. The pharmaceutical composition of claim 1 , wherein at least about 90% of the heavy chains consisting of the amino acid sequence of SEQ ID NO: 8 have one O-linked glycosylation.
9. The pharmaceutical composition of claim 1 , which is lyophilized.
10. The pharmaceutical composition of claim 1 , further comprising L-arginine HCl or L-arginine acetate.
11. The pharmaceutical composition of claim 10 , further comprising sucrose.
12. The pharmaceutical composition of claim 10 , further comprising mannitol.
13. A method for reversing or inhibiting anticoagulation in a patient undergoing an anticoagulation treatment with a factor Xa inhibitor, comprising administering to the patient a pharmaceutical composition of claim 1 .